NCT05294185

Brief Summary

Brain surgery operations include brain tumour removal and blood vessel procedures. Each year in the UK, approximately 70,500 patients are diagnosed with a brain tumour, 5,000 of whom undergo surgery. Approximately 1,000 patients undergo blood vessel brain surgery. Brain tumour surgery involves removing as much of the tumour as safely as possible. If all tumour is removed, patients have significantly better outcomes and live longer. However, even with the best hands and the most modern technology currently available, it is often not possible to reliably identify tumour during surgery. Moreover, nerves and blood vessels cannot be reliably identified either during surgery. Yet, they need to be preserved to avoid brain damage. Due to this uncertainty and the need to balance risks, tumour is often left behind. Today, close to 30% of brain tumour patients require repeat surgery owing to tumour left behind during their first surgery. Further surgeries are more difficult, pose additional patient risks and lead to increased healthcare costs with often poor patient outcomes. Newly developed camera systems have the potential to enhance the surgeon's vision to reliably identify tumour and healthy brain structures. Hyperspectral imaging (HSI) is one of the most promising of such technologies. Its core ability is to provide very detailed and rich information that is invisible to the human eye. HSI has demonstrated the potential to provide crucial, but currently unavailable, information about tumour and critical brain structures during surgery. However, HSI data is very complex and requires advanced computer-processing for its interpretation. In this project, we will use a HSI imaging system to record data in 81 patient undergoing brain including 63 patients with brain tumours and 18 patients suffering from brain vessel abnormalities. Using this data we will develop key computer-processing features to enable real-time image interpretation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
81

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 11, 2022

Completed
13 days until next milestone

First Posted

Study publicly available on registry

March 24, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

May 17, 2022

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2024

Completed
Last Updated

December 1, 2023

Status Verified

November 1, 2023

Enrollment Period

2.2 years

First QC Date

March 11, 2022

Last Update Submit

November 30, 2023

Conditions

Keywords

Hyperspectral imagingTissue perfusionTissue oxygenation

Outcome Measures

Primary Outcomes (1)

  • Correlation of HSI data with histological analysis of the corresponding biopsied pathological tissue

    To correlate HSI data with histological analysis of the corresponding biopsied pathological tissue and to correlate tissue perfusion and tissue oxygenation maps generated from the HSI data with the surgical timeline in patients undergoing neurovascular surgery.

    4-6 months

Secondary Outcomes (4)

  • Tissue perfusion and tissue oxygenation

    36 months

  • Safety of iHSI in Neurosurgery

    36 months

  • AI algorithm specificity

    36 months

  • Qualitative assessment

    36 months

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing neuro-oncology and neurovascular surgery

You may qualify if:

  • Adult patients aged 18 years and over
  • Patients with a diagnosis of a brain tumour (any type), AVM or aneurysm who are scheduled for elective surgery
  • Patients able to provide written informed consent

You may not qualify if:

  • Patients under 18 years of age
  • Patients who have previously had brain surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

King's College NHS Foundation Trust

London, SE5 9RS, United Kingdom

RECRUITING

Study Officials

  • Jonathan Shapey

    King's College London

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 11, 2022

First Posted

March 24, 2022

Study Start

May 17, 2022

Primary Completion

August 1, 2024

Study Completion

August 1, 2024

Last Updated

December 1, 2023

Record last verified: 2023-11

Locations